IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Sub sid iary of: Sandoz, Aus tria
Phar ma ceu ti cal Sales: US$ 4-5 mil lion
Prod ucts (% of Sales by Lead ing 5): 80-85%
Ther a peu tic Classes (% of Sales by Lead ing
5): 85-90%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
LINEX (antidiarrheal mi cro-or gan ism)
AMOKSIKLAV 2X (pen i cil lin broad spec trum)
BRONCHO MUNAL (vac cine other)
FERRUM LEK (iron plain/com bi na tion)
EDICIN (an ti bac te rial other)
Ther a peu tic Range:
antidiarrheals, elec tro lyte re plac ers, in tes ti nal
anti-inflammatorie s 37%
antibacterials sys temic 31%
vac cines 8%
antianemic prep a ra tions 8%
psycholeptics 4%
Lead ing Dose Forms:
cap sules 49%
tab lets 23%
coated tab lets 14%
liq uids 7%
in fu sions 4%
NOVARTIS
Full Name: Novartis Pharma Ser vices AG, Rep re -
sen ta tive & Re gional Of fice
Street Ad dress: Brivibas gatve 214b, 302 kab.,
LV-1039 Riga
Tel: +371 6 788 7070
Fax: +371 6 788 7077
Home Page: www.mea.novartis.com
Phar ma ceu ti cal Sales: US$ 4-5 mil lion
Prod ucts (% of Sales by Lead ing 5): 55-60%
Ther a peu tic Classes (% of Sales by Lead ing
5): 65-70%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
SANDOSTATIN LAR (hor mone hy po tha lamic)
LEPONEX (antipsychotic)
FEMARA (cytostatic hor mone an tag o nist)
SANDIMMUN NEORAL (immunosuppressive
agent)
Ther a peu tic Range:
antineoplastics 24%
immunosuppressive agents 15%
hor mones pi tu itary and hy po tha lamic 13%
psycholeptics 9%
cytostatic hor mone ther apy 7%
Lead ing Dose Forms:
tab lets 45%
coated tab lets 13%
vi als 13%
cap sules 11%
in fu sions 10%
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Con sumer Health Ser vices
SA
Street Ad dress: Kleistu 24, LV-1067 Riga
Tel: +371 6 744 1300
Fax: +371 6 744 1301
De scrip tion: Rep re sen ta tive of fice. Pro moter.
Prod uct ranges in clude: phar ma ceu ti cal prod ucts
(branded, non-pre scrip tion), med i cal equip ment.
Es tab lished 1997. 7 phar ma ceu ti cal employees in
2008.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 1-10 (2008)
Con tacts (Pharm): Chair man: Bjarne
Pedersen; Gen eral Con tact: Atvars Kurats
Phar ma ceu ti cal Sales: US$ 4-5 mil lion
Prod ucts (% of Sales by Lead ing 5): 55-60%
Ther a peu tic Classes (% of Sales by Lead ing
5): 85-90%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
THERAFLU NON-DROWS (cold prep a ra tion with -
out anti-in fec tive)
TAVEGYL (an ti his ta mine sys temic)
THERAFLU NIGHT TIM (cold prep a ra tion with out
anti-in fec tive)
VIBROCIL (na sal prep a ra tion top i cal)
OTRIVIN (na sal prep a ra tion top i cal)
Ther a peu tic Range:
cough and cold prep a ra tions 36%
na sal prep a ra tions 22%
an ti his ta mines sys temic 12%
dermatological antifungals 9%
antivaricosis/antihemorrhoidal prep a ra tions
9%
Lead ing Dose Forms:
pow ders/gran ules 34%
liq uids 27%
tab lets 13%
gels/sols 10%
creams 8%
© 2009 IMS Health In cor po rated or its af fil i ates Page 184